Vaccines work by training your immune system to recognize and fight specific germs, but they do this in several fundamentally different ways. The main types are live-attenuated, inactivated, toxoid, subunit/conjugate, viral vector, and nucleic acid (mRNA and DNA) vaccines. Each platform has distinct strengths, limitations, and practical differences that affect everything from how many doses you need to how the vaccine is stored.
Live-Attenuated Vaccines
Live-attenuated vaccines contain a weakened version of the actual virus or bacterium that causes disease. Because the germ is still alive, it replicates inside your body after vaccination, and a relatively small dose creates enough of the organism to trigger a strong, long-lasting immune response. This replication closely mimics a natural infection, which is why live vaccines often provide robust, sometimes lifelong, protection with just one or two doses.
The routinely recommended live vaccines in the United States include MMR (measles, mumps, rubella), chickenpox, rotavirus, and the nasal spray version of the flu vaccine. Other live vaccines exist for more specialized uses: the military uses a live adenovirus vaccine, and BCG (for tuberculosis) is widely used in other countries.
The trade-off is fragility. Live-attenuated vaccines can be damaged or destroyed by heat and light, so they require careful cold-chain storage. They’re also generally not recommended for people with severely weakened immune systems, since even the weakened germ could potentially cause problems in someone whose body can’t keep it in check.
Inactivated Vaccines
Inactivated vaccines use a killed version of the germ. Because the pathogen is completely dead, it can’t replicate in your body. This makes these vaccines very stable and safe for people with compromised immune systems, but it also means they produce a weaker immune response than live vaccines. You typically need multiple doses, plus periodic boosters, to build and maintain protection over time.
Common inactivated vaccines include those for hepatitis A, the injectable flu shot, polio (the injected version), and rabies. Many of these vaccines also include ingredients called adjuvants, substances that amplify the immune response to compensate for the fact that a dead germ doesn’t provoke the body as strongly on its own.
Toxoid Vaccines
Some diseases aren’t dangerous because of the bacteria themselves but because of the toxins those bacteria produce. Toxoid vaccines target the toxin rather than the germ. They’re made by taking the harmful toxin and inactivating it with a chemical (historically formaldehyde), creating a harmless version called a toxoid. Your immune system learns to neutralize the toxin, so even if you’re later infected, the bacteria’s weapon is disarmed.
Tetanus is the clearest example. The bacterium Clostridium tetani produces a toxin that interferes with nerve signaling, causing severe, uncontrolled muscle spasms that can be fatal. The tetanus toxoid vaccine, first developed in 1924, teaches the body to block this toxin before it reaches the nervous system. Diphtheria works the same way. Both are combined in the familiar Tdap and DTaP shots given in childhood and as adult boosters.
Subunit, Recombinant, and Conjugate Vaccines
Rather than using a whole germ (alive or dead), these vaccines use only specific pieces of the pathogen, typically a protein or sugar molecule from the germ’s outer surface. Because they contain only isolated components, there’s zero chance of causing even a mild version of the disease, making them suitable for almost anyone.
The terminology here reflects the manufacturing method. Recombinant vaccines use genetic engineering to produce a pathogen’s protein in a lab (the hepatitis B vaccine works this way). Conjugate vaccines attach a sugar molecule from a bacterium’s outer coating to a carrier protein, which helps the immune system, especially in young children, mount a stronger response. Pneumococcal and meningococcal vaccines for children use this conjugate approach. The whooping cough component of Tdap is also a subunit vaccine, using purified pieces of the pertussis bacterium.
Like inactivated vaccines, subunit and conjugate vaccines generally need adjuvants and multiple doses to produce lasting immunity.
Viral Vector Vaccines
Viral vector vaccines use a harmless, modified virus as a delivery vehicle. Scientists take a well-studied virus (often an adenovirus, which normally causes mild cold symptoms) and strip out its ability to cause disease. They then insert genetic instructions for a protein from the target pathogen. When the modified virus enters your cells, those cells follow the instructions to produce the target protein, and your immune system learns to attack it.
Adenoviral vectors are popular because they’re easy to produce in large quantities, can carry large stretches of genetic code, and are highly efficient at getting into cells. The Johnson & Johnson COVID-19 vaccine and several Ebola vaccines use this approach. Viral vector technology is also being explored as a platform for therapeutic vaccines against cancers and chronic infections like hepatitis B and C.
One limitation is pre-existing immunity: if your body has encountered the carrier virus before, it may partially neutralize the vaccine before it can do its job. This is why some viral vector vaccines use rare adenovirus types that most people haven’t been exposed to.
mRNA and DNA Vaccines
Nucleic acid vaccines represent the newest category. Instead of delivering a protein or a whole germ, they deliver genetic instructions (as mRNA or DNA) that tell your own cells to produce a specific protein from the target pathogen. Your immune system then responds to that protein, building the same kind of memory it would from an actual infection.
The Pfizer-BioNTech and Moderna COVID-19 vaccines are mRNA vaccines and the most widely used examples to date. mRNA is inherently fragile, which is why these vaccines require ultra-cold storage, but the technology has a major advantage: once the platform is established, updating the genetic sequence for a new variant or even a different disease is relatively fast compared to growing and purifying whole viruses.
DNA vaccines have been used in veterinary medicine for years and have recently crossed into human use. ZyCoV-D, a plasmid DNA-based COVID-19 vaccine approved in India, was a significant milestone. DNA vaccines are generally more stable at room temperature than mRNA vaccines, which could make them easier to distribute in resource-limited settings.
The Role of Adjuvants
Several vaccine types, particularly inactivated, toxoid, recombinant, and conjugate vaccines, include adjuvants: ingredients specifically designed to boost the immune response. Adjuvants work by helping immune cells take up the vaccine’s active ingredient more efficiently and keeping it available longer so the body has more time to learn from it.
Aluminum salts are the oldest and most common adjuvant, used in diphtheria, tetanus, and hepatitis B vaccines among others. Newer adjuvants include oil-in-water emulsions (used in some flu vaccines for older adults) and combinations of immune-stimulating molecules formulated in tiny fat bubbles called liposomes. The choice of adjuvant isn’t one-size-fits-all. Different formulations can shape both the strength and the type of immune response, allowing vaccine designers to optimize protection against specific pathogens.
Live-attenuated and mRNA vaccines typically don’t need adjuvants because they already provoke strong immune reactions on their own, either through replication of the weakened germ or through the way cells respond to foreign mRNA.